Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
TRO 19622 is an orally bioavailable mitochondrial-targeted neuroprotective agent that binds to and inhibits opening of the mitochondrial permeability transition pore (mPTP).1,2 It prevents mPTP opening induced by arachidonic acid (Item No. 90010) in HeLa cells when used at a concentration of 10 µM.1 TRO 19622 promotes survival of motor neurons in vitro in a concentration-dependent manner in the absence of neurotrophic factors (EC50 = 3.2 µM) and in vivo in a neonatal rat model of facial nerve axotomy when administered at a dose of 100 mg/kg per day.2 It delays onset of motor deficits and extends survival in the SOD1G93A transgenic model of amyotrophic lateral sclerosis (ALS). TRO 19622 (30 and 100 mg/kg) also increases the latency to paw withdrawal in a mechanical hyperalgesia test in rat models of streptozotocin-induced diabetic and vincristine-induced neuropathic pain but not in models of acute, inflammatory, or injury-induced pain.3
WARNING This product is not for human or veterinary use.
1. Olesoxime (TRO19622): A novel mitochondrial-
2. Identification and characterization of cholest-
3. Specific antinociceptive activity of cholest-